^
    Back
    Association details:
    Biomarker:BCR-ABL1 mutation
    Cancer:Chronic Myeloid Leukemia
    Drug:Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Special Drug Use-results Surveillance of Scemblix Tablets

    Excerpt:
    ...Type, frequency, seriousness, severity of AEs/treatment-related AEs of the safety analysis set`AEs leading to interruption/discontinuation in the safety analysis set`Frequency of AEs/treatment-related AEs summarized by patient characteristic factor`Type, frequency, seriousness, severity of AEs/treatment-related AEs in patients with special characteristics`AEs leading to interruption/discontinuation in patients with special characteristics`Type, frequency, seriousness, severity and outcome of AEs/treatment-related AEs by treatment line`Factors affecting occurrence of AEs by treatment line`AEs leading to interruption/discontinuation by treatment line`Major molecular response (MMR) rates`MMR rates by Week 48 by patient characteristics factor`MR4.0 and MR4.5 rates`Complete cytogenetic response (CCyR) rates`Complete hematological response (CHR) rates`Rate of patients with BCR-ABL1 gene mutations`MMR rates by Week 48 in patients with special characteristics`MMR rates by treatment line`MR4.0 and MR4.5 rates by treatment line`CCyR rates by treatment line`CHR rates by treatment line...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

    Excerpt:
    ...- At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to study treatment...
    Trial ID:
    ASC2ESCALATE
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

    Excerpt:
    ...- At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to study treatment...
    Trial ID:
    Ascembl
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

    Excerpt:
    ...- At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to current treatment...
    Trial ID:
    AIM4CML
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2021
    Title:

    ASCIMINIB RESPONSES IN PONATINIB-PRETREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA

    Published date:
    05/12/2021
    Excerpt:
    ...12 (39%) of the 31 patients displayed BCR-ABL1 mutations...Asciminib constitutes a valid treatment option for patients failing 2GTKIs.